Here Comes Sun’s US Cost-Saving Gleevec Generic

India’s Sun Pharma has launched its generic version of Novartis' blockbuster anticancer Gleevec in the US at savings of around 30%, putting the spotlight on the specialty segment which is probably, for the first time, witnessing genericization of such a high cost therapy.

More from India

More from Focus On Asia